Anzeige
Mehr »
Login
Dienstag, 24.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QN45 | ISIN: US0053291078 | Ticker-Symbol: 978
Frankfurt
23.12.24
15:29 Uhr
1,900 Euro
+0,010
+0,53 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
ADAGENE INC ADR Chart 1 Jahr
5-Tage-Chart
ADAGENE INC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
1,8001,86023.12.
1,7901,93023.12.

Aktuelle News zur ADAGENE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.11.Adagene reports new findings at SITC meeting3
07.11.Adagene präsentiert neue Forschungsergebnisse auf SITC-Tagung1
07.11.Adagene Inc.: Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination ...1
07.11.Adagene Inc. - 6-K, Report of foreign issuer-
ADAGENE Aktie jetzt für 0€ handeln
09.10.Adagene Inc.: Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting1
19.09.Adagene-Aktie behält Kaufempfehlung bei - ESMO-Daten Wirkstoffpotenzial bei MSS-CRC bestätigen3
19.09.Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC2
16.09.Adagene meldet vielversprechende Ergebnisse bei Krebstherapie6
16.09.Adagene reports promising cancer therapy results1
16.09.Adagene Inc. - 6-K, Report of foreign issuer1
16.09.Adagene Reports Encouraging Data From Phase 1b/2 Study Of ADG126 Plus Keytruda In Colorectal Cancer258BEIJING (dpa-AFX) - Adagene Inc. (ADAG) Monday announced new data from an ongoing phase 1b/2 trial of Adagene's ADG126 in combination with Merck's Keytruda for the treatment of colorectal cancer.The...
► Artikel lesen
16.09.Adagene Inc.: Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) ...2
23.08.SEBI bars Anil Ambani and 24 entities from securities market for 5 years over fraudulent scheme, shares of ADAG cos fall1
25.07.Adagene Inc. - 6-K, Report of foreign issuer1
12.07.Adagene Inc.: Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September125SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today...
► Artikel lesen
29.03.Adagene Inc.: Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update393- Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer...
► Artikel lesen
09.02.Adagene Inc.: Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with KEYTRUDA (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsat265- Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab anticipated in 2024 at a medical conference - - Initiated evaluation...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1